Another issue which makes little sense with the information in hand is the fact that price was pushed down ever since second ocular news came out, which were provided with a TH.
Price sank quickly down to the current trading range and stayed there since August/ Sept.
This made sense while negotiations in the US were ongoing and our case for business development partnerships shared by Sahm to the leading US biotech groups.
So why has price not changed and broker behaviour in parking us at this range not changed since that initiative was presumably delayed?
What is the purpose to hold us at a discount to CR levels from Oct 2020 for months on end if not for positioning?
There are elements to the story which are not shared is my conclusion and this might
cause a paradigm shift in the MC once it does.
all IMO
PYC Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)